Drug pricing regulator fixes prices of 40 formulation drugs

New Delhi: India’s drug pricing regulator on Tuesday capped the prices of 40 formulations, including statins and some other popular cardiovascular and diabetes drugs.“NPPA has fixed retail prices of 40 formulations under Drugs Prices Control Order (DPCO) 2013 based on its 75th authority meeting held on May 20, 2020,” the regulator said in a notification.The NPPA is mandated to revise the prices of drugs and formulations and to enforce price and availability of medicines in the country.According to the notification, the regulator has reduced the maximum retail price (MRP) of a new class of drugs, including statins, diabetes drugs, combination drugs like voglibose + metformin, glimepiride + metformin tablet, omeprazole + domperidone capsule (Oldolan), pantoprazole tablet (MyPrazol), glimepiride + metformin + pioglitazone tablet (MyGainPro P2), glimepiride + metformin + piaglitazone tablet (MyGainPro P1), pantoprazole +levosulpiride capsule (MyPrazol L), pantoprazole + domperidone tablet (MyPrazol D), losartan + hydrochlorothiazide tablet (MyLosdro H), telmisartan + amlodipine tablet (MyTenslo A), atorvastatin+ ezetimibe tablet, rabeprazole + domperidone tablet (Ridzogas D), and rabeprazole + domperidone capsule (Ridzogas SR D).76186951The revised prices will have an impact on the manufacturers of these formulations, including Sun Pharma and Zydus Healthcare.Under paragraph 2(u) of the DPCO, 2013, the manufacturer of the new formulations will have to fix the retail price as specified by the NPPA. “The manufacturer may add goods and services tax only if they have paid actually, or it is payable to the government on the retail price prescribed,” the NPPA said. The retail price for a pack of the formulation shall be arrived at by the manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where business is conducted in a manner so as to be easily accessible to any person wishing to consult the same.The manufacturers not complying with the ceiling price and notes specified will be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities (EC) Act, 1955.

from Economic Times https://ift.tt/3gNjwMO